Drugs / Influsplit Tetra™
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02218697 | Oct 2014 → Jan 2015 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials | ||||||
| Phase 3 | NCT06602024 Comparator | Sep 2024 → Aug 2025 | influenza | ModernaTX, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02207413 Comparator | Aug 2014 → Apr 2015 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03654937 Comparator | Sep → Dec 2016 | — | Saarland University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Influsplit Tetra | “Influenza vaccination "Influsplit Tetra" 2016/2017” NCT03654937 ↗ |
| Modality | Vaccine | “split-virion inactivated quadrivalent influenza vaccine (IIV4)” PMID 29669531 ↗ Apr 2018 |
| Route | Intramuscular | “Influsplit Tetra™ vaccine using a new manufacturing process administered intramuscularly (IM) in the deltoid region of non-dominant arm (Dose 1) in Adults Group” NCT02207413 ↗ |